Literature DB >> 17579084

Chronic sepsis mortality characterized by an individualized inflammatory response.

Marcin F Osuchowski1, Kathy Welch, Huan Yang, Javed Siddiqui, Daniel G Remick.   

Abstract

Late mortality in septic patients often exceeds the lethality occurring in acute sepsis, yet the immunoinflammatory alterations preceding chronic sepsis mortality are not well defined. We studied plasma cytokine concentrations preceding late septic deaths (days 6-28) in a murine model of sepsis induced by polymicrobial peritonitis. The late prelethal inflammatory response varied from a virtually nonexistent response in three of 14 to a mixed response in eight of 14 mice to the concurrent presence of nearly all measured cytokines, both proinflammatory and anti-inflammatory in three of 14 mice. In responding mice a consistent prelethal surge of plasma MIP-2 (1.6 vs 0.12 ng/ml in survivors; mean values), MCP-1 (2.0 vs 1.3 ng/ml), soluble TNF receptor type I (2.5 vs 0.66 ng/ml), and the IL-1 receptor antagonist (74.5 vs 3.3 ng/ml) was present, although there were infrequent increases in IL-6 (1.9 vs 0.03 ng/ml) and IL-10 (0.12 vs 0.04 ng/ml). For high mobility group box 1, late mortality was signaled by its decrease in plasma levels (591 vs 864 ng/ml). These results demonstrate that impeding mortality in the chronic phase of sepsis may be accurately predicted by plasma biomarkers, providing a mechanistic basis for individualized therapy. The pattern of late prelethal responses suggest that the systemic inflammatory response syndrome to compensatory anti-inflammatory response syndrome transition paradigm fails to follow a simple linear pattern.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17579084      PMCID: PMC4429887          DOI: 10.4049/jimmunol.179.1.623

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  Humane endpoints in shock research.

Authors:  Jean A Nemzek; Hong-Yan Xiao; Anne E Minard; Gerald L Bolgos; Daniel G Remick
Journal:  Shock       Date:  2004-01       Impact factor: 3.454

Review 2.  Novel therapies for sepsis: a review.

Authors:  Katherine J Deans; Michael Haley; Charles Natanson; Peter Q Eichacker; Peter C Minneci
Journal:  J Trauma       Date:  2005-04

Review 3.  Sepsis and septic shock--a review of laboratory models and a proposal.

Authors:  K A Wichterman; A E Baue; I H Chaudry
Journal:  J Surg Res       Date:  1980-08       Impact factor: 2.192

4.  Immunopathologic alterations in murine models of sepsis of increasing severity.

Authors:  S Ebong; D Call; J Nemzek; G Bolgos; D Newcomb; D Remick
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

Review 5.  Sepsis syndromes: understanding the role of innate and acquired immunity.

Authors:  A Oberholzer; C Oberholzer; L L Moldawer
Journal:  Shock       Date:  2001-08       Impact factor: 3.454

6.  In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic mice.

Authors:  Doreen E Wesche-Soldato; Chun-Shiang Chung; Joanne Lomas-Neira; Lesley A Doughty; Stephen H Gregory; Alfred Ayala
Journal:  Blood       Date:  2005-06-07       Impact factor: 22.113

7.  Antibiotic treatment influences outcome in murine sepsis: mediators of increased morbidity.

Authors:  D Newcomb; G Bolgos; L Green; D G Remick
Journal:  Shock       Date:  1998-08       Impact factor: 3.454

8.  Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release.

Authors:  Rosa C S Vianna; Rachel N Gomes; Fernando A Bozza; Rodrigo T Amâncio; Patrícia T Bozza; Cid M N David; Hugo C Castro-Faria-Neto
Journal:  Shock       Date:  2004-02       Impact factor: 3.454

9.  Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-1ra Phase III Sepsis Syndrome Study Group.

Authors:  W A Knaus; F E Harrell; J F LaBrecque; D P Wagner; J P Pribble; E A Draper; C J Fisher; L Soll
Journal:  Crit Care Med       Date:  1996-01       Impact factor: 7.598

10.  Reversing established sepsis with antagonists of endogenous high-mobility group box 1.

Authors:  Huan Yang; Mahendar Ochani; Jianhua Li; Xiaoling Qiang; Mahira Tanovic; Helena E Harris; Srinivas M Susarla; Luis Ulloa; Hong Wang; Robert DiRaimo; Christopher J Czura; Haichao Wang; Jesse Roth; H Shaw Warren; Mitchell P Fink; Matthew J Fenton; Ulf Andersson; Kevin J Tracey
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-26       Impact factor: 11.205

View more
  46 in total

1.  Hematopoietic stem-progenitor cells restore immunoreactivity and improve survival in late sepsis.

Authors:  Laura Brudecki; Donald A Ferguson; Deling Yin; Gene D Lesage; Charles E McCall; Mohamed El Gazzar
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

2.  Adenosine negative feedback on A2A adenosine receptors mediates hyporesponsiveness in chronically septic mice.

Authors:  Bryan Belikoff; Stephen Hatfield; Michail Sitkovsky; Daniel G Remick
Journal:  Shock       Date:  2011-04       Impact factor: 3.454

3.  Host derived biomarkers of inflammation, apoptosis, and endothelial activation are associated with clinical outcomes in patients with bacteremia and sepsis regardless of microbial etiology.

Authors:  William O Hahn; Carmen Mikacenic; Brenda L Price; Susanna Harju-Baker; Ronit Katz; Jonathan Himmelfarb; Mark M Wurfel; W Conrad Liles
Journal:  Virulence       Date:  2016-01-28       Impact factor: 5.882

4.  Stratification is the key: inflammatory biomarkers accurately direct immunomodulatory therapy in experimental sepsis.

Authors:  Marcin F Osuchowski; Judith Connett; Kathleen Welch; Jill Granger; Daniel G Remick
Journal:  Crit Care Med       Date:  2009-05       Impact factor: 7.598

5.  Functions of the complement components C3 and C5 during sepsis.

Authors:  Michael A Flierl; Daniel Rittirsch; Brian A Nadeau; Danielle E Day; Firas S Zetoune; J Vidya Sarma; Markus S Huber-Lang; Peter A Ward
Journal:  FASEB J       Date:  2008-06-27       Impact factor: 5.191

6.  MicroRNA-146a regulates both transcription silencing and translation disruption of TNF-α during TLR4-induced gene reprogramming.

Authors:  Mohamed El Gazzar; Ashley Church; Tiefu Liu; Charles E McCall
Journal:  J Leukoc Biol       Date:  2011-05-11       Impact factor: 4.962

7.  Cecal ligation and puncture-induced impairment of innate immune function does not occur in the absence of caspase-1.

Authors:  E D Murphey
Journal:  J Immunol       Date:  2011-06-15       Impact factor: 5.422

8.  Anti-inflammatory effects of miR-21 in the macrophage response to peritonitis.

Authors:  Rebecca Elise Barnett; Daniel J Conklin; Lindsey Ryan; Robert C Keskey; Vikram Ramjee; Ernesto A Sepulveda; Sanjay Srivastava; Aruni Bhatnagar; William G Cheadle
Journal:  J Leukoc Biol       Date:  2015-09-17       Impact factor: 4.962

9.  Noninvasive model of sciatic nerve conduction in healthy and septic mice: reliability and normative data.

Authors:  Marcin F Osuchowski; James Teener; Daniel Remick
Journal:  Muscle Nerve       Date:  2009-10       Impact factor: 3.217

10.  Sepsis chronically in MARS: systemic cytokine responses are always mixed regardless of the outcome, magnitude, or phase of sepsis.

Authors:  Marcin F Osuchowski; Florin Craciun; Katrin M Weixelbaumer; Elizabeth R Duffy; Daniel G Remick
Journal:  J Immunol       Date:  2012-09-24       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.